Table 2.

Inhibitory effects of clopidorel (n = 12) and Prasugrel (n = 12) on platelet aggregation and systemic TAT levels in PCI patients.

Agonist	Time (hour)	Clopidogrel inhibition (% ± SE)	Prasugrel inhibition (% ± SE)	p-value
ADP	1	38 ± 10	84 ± 9	< 0.0001
20 μM	2	53 ± 10	94 ± 5
	4	72 ± 8	98 ± 1
	16	85 ± 3	98 ± 1
SFLLRN	1	2 ± 8	62 ± 9	< 0.0001
5 μM	2	9 ± 8	64 ± 10
	4	17 ± 8	75 ± 6
	16	15 ± 8	58 ± 7
AYPGKF	1	7 ± 3	39 ± 9	< 0.0001
160 μM	2	9 ± 3	44 ± 11
	4	13 ± 4	53 ± 8
	16	11 ± 4	41 ± 10
Collagena	1	34 ± 11	56 ± 8	0.06
5 μg/mL	2	39 ± 9	61 ± 6
	4	58 ± 8	67 ± 4
	16	48 ± 8	61 ± 8
TAT	0	258 ± 39	251 ± 27	NS
pmol/L	1	274 ± 82	179 ± 23	NS
	2	180 ± 23	226 ± 35	NS
	4	284 ± 34	224 ± 15	NS
	16	151 ± 10	301 ± 45	0.007

Platelets in PRP were isolated from PCI patients at baseline and after 1, 2, 4 and 16 h after bivalirudin infusion and clopidogrel and prasugrel loading dose administration, and were stimulated with 20 μM ADP, 5 μM SFLLRN, 160 μM \AYPGKF and 5 μg/L collagen. TAT levels in plasma were analyzed by ELISA as described in the methods. Data are reported as Mean ± SD and p values were determined by one-way ANOVA repeated measure test. TAT statistical analyses were performed using two-tailed student’s t-test.

^aCollagen-dependent aggregation was measured with 18 of the 24 PCI patients as shown in Fig. 4A for individual patients.